<DOC>
	<DOCNO>NCT00712426</DOCNO>
	<brief_summary>Huntington 's disease ( HD ) slowly progressive disorder devastate life affected family . There treatment slow progression HD , mildly effective symptomatic therapy available.Creatine monohydrate consider nutritional supplement . The purpose CREST-E test whether high-dose creatine slow progressive functional decline occur person 18 year old early clinical feature HD . The long-term safety , tolerability effectiveness 40 gram daily creatine compare placebo study . A variety biological process assess marker disease activity progression creatine effect . Up 50 active research center globally enroll 650 subject .</brief_summary>
	<brief_title>Creatine Safety , Tolerability , &amp; Efficacy Huntington 's Disease ( CREST-E )</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Male female age 18 older . Clinical feature HD AND confirmatory family history HD ; OR Clinical feature HD AND CAG repeat expansion great equal 36 . Stage I II illness ( TFC great equal 7 ) . Ambulatory require skilled nurse care time enrollment . Must capable providing inform consent comply trial procedure . Additional inclusion criterion apply . History known sensitivity intolerability creatine monohydrate . Exposure investigational drug within 30 day randomization ( Baseline visit ) . Use supplemental creatine dose great 10 gram within 30 day randomization ( Baseline visit ) . Screening laboratory abnormality judgment investigator would jeopardize safe conduct study . Clinical evidence unstable medical illness . Clinical evidence unstable psychiatric illness . Additional exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Huntington 's disease</keyword>
	<keyword>Creatine</keyword>
	<keyword>Mitochondrial Dysfunction</keyword>
	<keyword>Total Functional Capacity</keyword>
	<keyword>UHDRS</keyword>
</DOC>